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Abstract
Patients with renal diseases are prone to both thrombosis and bleeding, as they have 
profound changes in all three classic components of coagulation, defined approximately 
150 years ago by Virchow: blood flow, vessel wall (endothelial injury), and coagulation 
properties of the blood (e.g., coagulation and fibrinolytic systems and platelets). The pro‐
thrombotic state in chronic kidney disease (CKD), glomerular diseases (including sys‐
temic lupus and vasculitis), and some less frequent conditions (idiopathic retroperitoneal 
fibrosis, antiphospholipid syndrome, hemolytic‐uremic syndrome, etc.) is associated 
with vascular endothelial damage, increase in certain coagulation and antifibrinolytic 
factors, decrease in anticoagulation proteins, dyslipidemia, hypoalbuminemia, changes 
in platelet membranes, hemo‐ and peritoneal dialysis and heparin treatment, increased 
microRNAs and circulating microparticles, antiphospholipid antibodies, nephrotic syn‐
drome, anemia with high platelet count, and so on. Nevertheless, the same patients have 
substantially increased risk of bleeding due to platelet dysfunction and intake of certain 
medications (antiaggregants, heparin and low‐molecular weight heparins, and anemia). 
The aim of this review is to present the main thrombo‐embolic risk factors in a wide vari‐
ety of patients with renal diseases, including chronic glomerulonephritis (primary and 
secondary), chronic renal disease, and idiopathic retroperitoneal fibrosis. We have evalu‐
ated the risk factors for arterial and venous thromboses in a wide variety of renal patients 
with both glomerular and non‐glomerular diseases, including the presence of nephrotic 
syndrome, inborn and acquired coagulation defects (i.e., factor V Leiden, MTHFR gene 
mutation, 20210 prothrombin gene mutation, and antiphospholipid antibodies), cortico‐
steroid treatment, and dyslipidemia. We are describing the results of these investigations 
and suggesting prophylactic anticoagulant strategies in such patients. Multiple risk fac‐
tors influence the coagulation system in renal disease leading to both hypercoagulation 
and hemorrhagic diathesis. Therefore, renal patients should be thoroughly investigated 
for coagulation abnormalities, especially if pathogenic (i.e., corticosteroid and immu‐
nosuppressive) and anticoagulation treatment is to be initiated. Moreover, the doses of 
anticoagulant/antiaggregant and hemostatic medications should be considered carefully, 
having in mind the underlying diseases and risk factors, renal function, and concomitant 
treatment.
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Patients with renal diseases are prone to both thrombosis and bleeding, as they have pro‐
found changes in all three classic components of coagulation, defined approximately 150 
years ago by Virchow: blood flow, vessel wall (endothelial injury), and coagulation properties 
of the blood (e.g., coagulation and fibrinolytic systems, platelets). In this aspect, chronic kid‐
ney disease (CKD) is a unique state with the simultaneous presentation of both thrombophilia 
and hemorrhagic diathesis.
The prothrombotic state in CKD, glomerular diseases (including systemic lupus and vasculitis), 
and some less frequent conditions (idiopathic retroperitoneal fibrosis (RPF), antiphospholipid 
syndrome (APS), hemolytic‐uremic syndrome, etc.) is associated with [1–10]:
• vascular endothelial damage,
• increase in certain coagulation and antifibrinolytic factors,
• decrease in anticoagulation proteins,
• dyslipidemia,
• nephrotic syndrome and hypoalbuminemia,
• changes in platelet membranes,
• hemo‐ and peritoneal dialysis (PD) and heparin treatment,
• increased microRNAs and circulating microparticles (MPs),
• antiphospholipid antibodies,
• anemia with high platelet count, and so on.
Nevertheless, the same patients have substantially increased risk of bleeding due to [6–8]:
• platelet dysfunction,
• impaired platelet‐vessel wall interactions,
• intake of certain medications (antiaggregants, heparin and low‐molecular weight heparins 
(LMWHs), and anemia),
• vascular wall abnormalities,
• accompanying disease and conditions (i.e., anemia, myeloma, amyloidosis, etc.), and
• dialysis treatment.
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2. Overview of coagulation abnormalities in renal diseases
Renal diseases have high prevalence among the population worldwide. On the other hand, 
thrombo‐embolic complications, including large vascular thromboses (stroke and myocar‐
dial infarction and peripheral arterial disease), deep vein thrombosis (DVT) and pulmonary 
embolism (PE), venous access thromboses, placental thromboses, thromboses of retinal vein 
and/or arteries, and so on, are also very prevalent in adults, especially in the groups > 65 
years of age. Due to the specific metabolic, vascular, plasma, and platelet changes and at 
the background of inborn hemostasis and bleeding disorders, renal diseases can be associ‐
ated with both hypercoagulation (thrombophilia) and bleeding (hemorrhagic diathesis) [3–7]. 
Moreover, CKD itself, irrespective of its underlying cause, is a major risk factor for thrombo‐
embolic complications [4–8, 10].
2.1. Hypercoagulation
The underlying mechanism of thrombophilia in renal disease, including CKD and chronic renal 
failure (CRF), is associated with platelet abnormalities, coagulation cascade changes, anemia, 
endothelial dysfunction and damage, circulating microparticles and miRNAs, atherosclero‐
sis, inborn (protein S and C and anti‐thrombin III deficiency, 20210 prothrombin gene muta‐
tion, methylene tetrahydrofolate reductase (MTHFR) gene mutation, factor V Leiden, etc.) 
and acquired thrombophilia (antiphospholipid syndrome and nephrotic syndrome), intake 
of certain medications and illicit drugs (including corticosteroids, cocaine, heparin, etc.), 
and dialysis [6–8, 10]. All these changes could be summarized as: increased platelet activa‐
tion/aggregation, activated coagulation and decreased endogenous anticoagulation, and 
decreased fibrinolysis.
2.1.1. Platelet abnormalities/dysfunction
In catabolic patients, especially on peritoneal dialysis, it has been shown that decreased 
plasma levels of nitric oxide (NO) and l‐arginine are associated with increased platelet aggre‐
gation. Moreover, the increase of phosphatidylserine on platelet surface in CKD/CRF leads to 
activation of caspase‐3 and binding of factor V with subsequent thrombin formation. Besides, 
CKD/CRF patients have increased PAC‐1 fibrinogen receptor and circulating P‐selectin that 
lead to formation of platelet‐leukocyte aggregates and formation of free oxygen radicals lead‐
ing to increased tendency toward thrombosis.
In dialysis, especially in peritoneal dialysis (PD), hypoalbuminemia is thought to lead to 
platelet activation.
It should be mentioned that in CKD/CRF, there are other functional platelet abnormalities asso‐
ciated with increased bleeding tendency, including decreased GPIb on platelet surface, sup‐
pressed function of GPIIb/IIIa, inhibited platelet aggregation changes in platelet alpha‐granules, 
changes in calcium levels, abnormalities in prostaglandin and arachidonic acid metabolism, 
increased circulating fibrinogen fragments, uremic toxins that inhibit both thrombopoiesis in 
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the bone marrow and platelet aggregation, amyloid deposition in the vessel walls and bone 
marrow inhibits platelet‐vessel wall interactions and thrombopoiesis, and so on.
Paradoxically, in patients with CRF, the described platelet adhesion defects are accompanied 
by hypercoagulation due to endothelial damage and increased coagulation factor levels and 
activity plus decreased fibrinolytic activity.
2.1.2. Coagulation cascade abnormalities
CKD/CRF is a well‐known pro‐inflammatory state with increased acute‐phase proteins 
(including C‐reactive protein [CRP] and coagulation factors, i.e., fibrinogen) and interleukin 
6 (IL‐6), increased plasma tissue factor (TF) levels, increased nuclear factor kappa‐B (NF‐kB) 
and PAR‐1 receptor, decreased levels and activity of anti‐thrombin III. On the other hand, 
in CKD and CRF, marked activation of rennin‐angiotensin‐aldosterone system (RAAS) is 
described with increase in plasma fibrinogen levels and plasminogen activator inhibitor 1 
(PAI‐1). The latter mechanism is associated with both prothrombotic state and progression of 
CKD itself and closes a vicious circle of CKD—hypertension and prothrombotic state—CKD 
progression and thrombosis, leading to further worsening of CKD and thromboses.
In (auto)immune renal diseases, hypercoagulability state is due to increased acute‐phase pro‐
teins and coagulation cascade factors plasma levels and vascular wall/endothelial abnormali‐
ties with or without concomitant platelet count and/or activation changes.
2.1.3. Anemia
Anemia in CKD is due to erythropoietin deficiency, iron deficiency due to malabsorption of iron + 
chronic gastrointestinal tract (GIT) bleeding + intake of medications + folic acid and B12 deficiency 
+ chronic inflammation and hypercatabolic state. Anemia is associated with both thrombophilia 
(especially in cases with chronic bleeding and compensatory increase in platelet count) and bleed‐
ing tendency (due to affection of platelet‐vessel wall interaction, decreased release of adenosine 
diphosphate (ADP) and decreased scavenging of NO, inactivation of prostaglandin I2 [PGI2]). 
The correction of anemia with erythropoiesis‐stimulating agents is also a double‐edged sword; it 
can lead to the correction of bleeding tendency but it could also increase blood viscosity and arte‐
rial pressure and lead to increased incidence of stroke and myocardial infarction.
2.1.4. Endothelial dysfunction and damage
Endothelial dysfunction and damage in CKD/CRF is associated with changes in tissue plas‐
minogen activator (tPA), PAI‐1 and von Willebrand factor (vWF) secretion and in NO synthesis 
and secretion. These alterations, as it has been mentioned above, can lead to both hyper‐ and 
hypocoagulation due to impaired platelet‐vessel wall interaction and changes in vascular 
tone and inflammatory response (including oxygen radical generation and scavenging).
Another suspected culprit for the development of hypercoagulation in CKD/CRF is hyper‐
homocysteinemia leading to endothelial damage, changes in fibrin formation tPA secretion, 
increase in PAI1, and metalloproteinase‐9 activity.
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In renal transplantation (RT) patients, the calcineurin inhibitor and/or azathioprine‐induced 
endothelial damage + corticosteroid treatment could lead to hypercoagulation and venous 
thromboembolism (VTE).
In illicit drug users, the intake of heroin, cocaine, and amphetamines has been associated with 
both renal damage (marked vasoconstriction, rhabdomyolysis, and glomerulosclerosis) and 
thrombosis (thrombotic microangiopathy due to endothelial damage) [11]. Moreover, in her‐
oin‐dependent subjects, drug‐induced antiphospholipid antibodies with thrombo‐embolic 
complications have been described [11, 12].
2.1.5. Microparticles
Microparticles (MPs) are cell‐membrane residues containing phospholipids (phosphatidyl‐
serine) and proteins (tissue factor, residues of cell receptors, etc.). MPs are formed during 
different processes, such as cell development, differentiation and aging, inflammation, and 
cell death. MPs are known to have pro‐coagulant effects due to phosphatidylserine and TF. 
Sometimes MPs are associated with small and presumed non‐coding single‐stranded RNA 
molecules, called microRNAs (miRNAs). These miRNAs are known to participate in post‐tran‐
scriptional gene modulation. It has been discovered that they can modulate platelet function 
via the P2Y12 receptor and/or the VAMP8 or via influencing the platelet mRNA regulation.
2.1.6. Atherosclerosis and vascular injury
Atherosclerosis is a well‐known and independent risk factor for the development of large vas‐
cular incidents (including stroke and myocardial infarction). All CKD/CRF patients, especially 
in the presence of nephrotic syndrome, chronic inflammation, and corticosteroid treatment, 
have accelerated atherosclerosis development. Moreover, the co‐morbidities in atherosclerosis 
and CKD/CRF patients (diabetes, hypertension, obesity, and dyslipidemia) also predispose to 
both arterial and venous thromboses, probably via following mechanisms: endothelial/ves‐
sel wall injury and platelet dysfunction. Microalbuminuria, a marker of endothelial injury, is 
associated with the risk for the development of both arterial and venous thromboses.
2.1.7. Hypercoagulation in glomerulonephritis
In patients with glomerular diseases, hypercoagulation is associated with four major factors: 
nephrotic syndrome, vasculitis and vascular wall inflammation, and medications (corticoste‐
roids and cyclosporine A).
The nephrotic syndrome leads to hypercoagulation due to imbalance between pro‐and anti‐
coagulation factors: decreased protein C and S and anti‐thrombin III, decreased fibrinolysis, 
and increased coagulation factor plasma levels. The development of DVT and/or PE is one of 
the major complications of the nephrotic syndrome. The latter substantially increases the risk 
for venous thromboembolism.
Vasculitis/vascular wall inflammation in systemic and renal vasculitis, including antineutro‐
phil cytoplasmic antibody (ANCA)‐positive cases, leads to hypercoagulation due to structural 
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changes in the vessel wall, endothelial damage, and dysfunction and activation of coagulation 
cascade. Moreover, high platelet count is observed in acute and chronic inflammation.
Rarely, in patients with systemic vasculitis, parenchymal organ bleeding has been described, asso‐
ciated with microvascular damage and development of small cracks filled with blood (peliosis).
The intake of corticosteroids is associated with increased platelet count and aggregability, 
increase in coagulation factors plasma levels, and in acute‐phase proteins. On the other hand, 
corticosteroid treatment is associated with the development of GIT hemorrhages due to the 
inhibition of prostaglandin synthesis. Cyclosporine A treatment can lead to endothelial cell 
damage with the subsequent development of hypercoagulation and thrombotic microangi‐
opathy. Cocaine, amphetamines, and heroin also affect endothelial cells and can lead to the 
development of thrombotic microangiopathy.
2.1.8. Antiphospholipid antibodies (APLs)
These autoantibodies are directed against negatively charged plasma or membrane phospho‐
lipids and/or phospholipid binding proteins and/or phospholipid‐protein complexes. They 
are the major laboratory criterion for the classification of the antiphospholipid syndrome. 
APLs affect not only the coagulation system but also endothelial function and platelets. They 
are known to cause both arterial and venous thromboses, low platelet count, reproductive 
failure, and accelerated atherosclerosis.
Their determination in renal diseases is crucial because the results can affect both the diagno‐
sis (particularly in chronic glomerulonephritis patients in whom systemic lupus erythematosus 
(SLE) is suspected) and the treatment, especially at the background of other thrombophilic fac‐
tors, such as nephrotic syndrome, corticosteroid treatment, vasculitis, dyslipidemia, and diabetes.
The suspected pathogenic mechanism of the pro‐coagulant action of APL and the develop‐
ment of vascular injury are [13–18]:
• inhibition of the activated protein C,
• activation of the tissue factor,
• inhibition of anti‐thrombin III,
• damage of the membrane annexin V,
• inhibition of the anticoagulant activity of beta‐2‐glycoprotein‐I (b2GPI),
• inhibition of fibrinolysis,
• endothelial cell activation,
• increased expression of adhesion molecules on endothelial cells and leukocyte adhesion to 
the vascular endothelium,
• neutrophil leukocyte activation and degranulation,
• increased platelet activation and aggregation,
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• increased adhesion of b2GPI and prothrombin to the cell membranes,
• effect on endothelial cell apoptosis,
• inhibition of the prostacyclin secretion from endothelial cells, and
• accelerated atherosclerosis.
On the other hand, APLs have several anticoagulant effects, associated with inhibition of fac‐
tor IX and X activation and of the conversion of prothrombin to thrombin [14]. The factors that 
modulate the pro‐ and anticoagulant effects of ALA probably are the phospholipids that bind 
APL and the antigenic specificity of the latter.
The development of thrombosis in APL‐positive patients has been explained by the so‐called 
second‐hit theory: the presence of APL (first hit) itself is not sufficient for the generation of 
thrombus but when a second abnormality develops (i.e., endothelial damage, platelet dys‐
function, etc.), thrombus may be formed [14]. Moreover, APL could represent the second 
hit—at the background of inborn or acquired thrombophilia: factor V Leiden or prothrombin 
gene mutation, MTHFR, protein C/S or anti‐thrombin deficiency, nephritic syndrome, chronic 
renal failure, chronic endothelial damage or dysfunction in chronic inflammation, corticoste‐
roid treatment, and so on. In APS patients, we showed increased platelet activation markers’ 
expression [16]. Some of the APS patients have other underlying inborn coagulation defi‐
ciency [18]: protein S/C or anti‐thrombin III deficiency, factor V Leiden, 20210 prothrombin 
gene mutation. This fact supports the described second‐hit theory.
2.1.9. Heparin‐induced thrombocytopenia type II (HIT II)
HIT II is associated with the heparin‐induced synthesis of platelet‐activating antibodies 
against the complex heparin‐platelet factor 4. It is observed in 0.5–5% of all heparin‐treated 
patients. In such patients, platelet levels are low but thrombo‐embolic complications (usually 
venous thromboses) appear due to platelet activation.
2.2. Bleeding tendency (hemorrhagic diathesis)
The underlying mechanisms of hemorrhagic diathesis in renal diseases, CKD and CRF, are asso‐
ciated with platelet dysfunction, uremic toxins, dialysis membranes, impaired platelet‐vessel 
wall interaction, anemia, and intake of certain medications (including aspirin and non‐steroid 
anti‐inflammatory drugs [NSAIDs], anticoagulants, antiaggregants, and antibiotics) [6–8].
2.2.1. Platelet dysfunction
The main cause of hemorrhagic diathesis in chronic renal diseases, CKD and CRF, are platelet 
abnormalities, including low platelet count in CKD/CRF due to bone marrow suppression 
and/or immune thrombocytopenia, changes in alpha‐granules with increased adenosine tri‐
phosphate (ATP)/ADP ratio, and reduced serotonin content, dysregulation of arachidonate 
and prostaglandin synthesis and degradation (mainly decreased thromboxane A2), increased 
plasma levels of fibrinogen fragments.
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The changes in alpha‐granules are associated with decreased platelet factor 4, fibronectin B, 
platelet‐derived growth factor, vWF, fibrinogen, serotonin, factors V and XIII, transforming 
growth factor B, and so on.
2.2.2. Uremic toxins
In CKD and CRF, several uremic toxins affect platelet degranulation and adhesion: phenol and 
phenolic acid, guanidinosuccinic acid, middle molecules (molecular weight of 500–3000 Da). 
Moreover, uremic toxins inhibit thrombopoiesis in the bone marrow. Low calcium levels in 
CKD/CRF can also contribute to hypocoagulation. Hemodialysis (HD) and peritoneal dialysis 
have dual and controversial effect on bleeding and coagulation. Both methods are associated 
with hypercatabolism, pro‐inflammatory state, malabsorption, anemia, and low calcium that 
could cause both bleeding and hypercoagulation. Moreover, the administration of heparin 
could cause both bleeding and thromboses (HIT II).
Parathyroid hormone (PTH) has been shown to inhibit platelet aggregation (at least in 
vitro). In hemodialysis, the dialysis membrane can lead to platelet activation and aggre‐
gation, but the removal of uremic toxins can (at least partially) correct coagulation 
abnormalities.
And, finally, circulating fibrinogen fragments that are elevated in CKD/CRF can competi‐
tively bind to GPIIb/IIIa platelet receptors and decrease platelet adhesion and aggregation.
2.2.3. Dialysis membranes
Dialysis membranes lead to persistent platelet activation (including increased number and 
percentage of P‐selectin/CD63‐positive circulating platelets), formation of platelet‐leuko‐
cyte (with the generation of free oxygen radicals), and platelet‐erythrocyte aggregates [9]. 
The process of platelet activation is dependent on the type of dialyzer membranes used 
(more pronounced in cellulose diacetate and polysulfone membranes and less severe in 
EVAL membranes). The persistent chronic inflammation and hypercatabolism in CRF/CKD 
also contribute to hypercoagulation. Yet, some patients on dialysis develop thrombocytope‐
nia with bleeding diathesis.
The dialysis (HD and continuous ambulatory peritoneal dialysis [CAPD]) is known to correct, 
at least partially, the coagulation abnormalities in CKD/CRF.
2.2.4. Platelet‐vessel wall interaction
Platelet‐vessel wall interactions are associated with the binding of platelets to vWF and fibrin‐
ogen on endothelial surface and the activation of platelet receptors (GPIb and GPIIa/IIIb). In the 
hypercatabolic environment of CKD/CRF, significant decrease of platelet GPIb has been 
reported, along with decreased platelet binding to fibrinogen and vWF (plus decreased vWF 
levels), decreased activation of GPIIa/IIIb [6]. The impaired platelet adhesion is thought 
to be caused by dialyzable uremic toxins, as dialysis corrects the described abnormalities. 
Moreover, the administration of vWF‐containing cryoprecipitates and of desmopressin (known 
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to stimulate endothelial release of vWF) has been shown to ameliorate platelet‐vessel wall inter‐
actions. And finally, the changes in vascular tone in response to vasoactive substances (nitric 
oxide and prostacyclin) associated with the accumulation of uremic toxins also contribute to 
the impairment of platelet‐endothelial interactions.
2.2.5. Anemia
Anemia is known to directly influence bleeding because red blood cells lead to platelet 
aggregation and stimulate ADP release and PGI2 inactivation. Moreover, in patients with 
CKD/CRF, the infusion of red blood cells and/or the correction of erythrocyte levels with 
erythropoiesis‐stimulating agents and iron lead to reduction of bleeding time. On the other 
hand, one should not forget that the correction of anemia increases the risk for major vascu‐
lar incidents (myocardial infarction and stroke).
2.2.6. Drugs and medications
In patients with renal diseases, many drugs may cause severe bleeding episodes, even life‐
threatening, due to changes in the drug clearance and drug accumulation anticoagulants: 
direct thrombin inhibitors, aspirin and non‐steroid anti‐inflammatory drugs [NSAIDs], 
interaction with platelet membranes (beta‐lactam antibiotics, inhibition of cyclooxygenase 
(aspirin and NSAIDs).
In patients with opioid dependence, Savona et al. [19] describe heroin‐induced autoimmune 
thrombocytopenia. Moreover, in heroin and cocaine/amphetamine dependency, the develop‐
ment of endothelial drug injury may lead to thrombotic microangiopathy with both throm‐
boses and bleeding [11].
The underlying mechanisms for the development of hypercoagulation and bleeding tendency 
in CKD are summarized in Table 1.
The main clinical presentations of thromboses in renal diseases are summarized in Table 2.
Hypercoagulation Bleeding
Platelet activation Platelet defects
Vascular endothelial damage Impaired platelet‐vessel wall activations
Microparticles and micro RNA Vascular damage
Oxidative stress Oxidative stress
Increased von Willebrand factor (vWF) Defective binding of vWF to GPIIb/IIIa
Increased Defective prostacyclin and NO synthesis
Increased factor XIIa and VIIa and thrombin formation Anemia
Decreased protein C and protein S and anti‐thrombin III
Increased tissue factor and acute‐phase proteins: fibrinogen, 
CRP
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Hypercoagulation Bleeding
Decreased tissue plasminogen activator (tPA) Increased tPA
Increased plasminogen activator inhibitor 1 (PAI1) Decreased PAI1
Uremic toxins Uremic toxins
Increased rennin‐angiotensin‐aldosterone (RAAS) activity
Antiphospholipid antibodies
 ‐ Pro‐thrombotic gene mutations
 ‐ Factor V Leiden
 ‐ MTHFR
 ‐ 20210 prothrombin gene mutation
 ‐ Protein C, S, and anti‐thrombin deficiency
Medications
 ‐ Beta‐lactam antibiotics
 ‐ Aspirin and NSAIDs
 ‐ Anticoagulants
 ‐ Antiaggregants
Nephrotic syndrome Amyloidosis, myeloma
Anemia Anemia
Atherosclerosis: dyslipidemia, diabetes, arterial hypertension, 
peripheral vascular disease
Vasculitis
Corticosteroid treatment, cyclosporine A, cocaine Corticosteroid treatment
Heparin‐induced thrombocytopenia type II
Hemodialysis and peritoneal dialysis Hemodialysis and peritoneal dialysis
Table 1. Factors leading to coagulation abnormalities in renal diseases.
Hypercoagulation
 ‐ Venous thromboembolism (deep venous thrombosis [DVT] and/or pulmonary embolism [PE]).
 ‐ Major vascular incidents (myocardial infarction and/or stroke, peripheral arterial disease).
 ‐ Hemodialysis vascular access and/or central venous access thrombosis.
 ‐ Peripheral vascular access thrombosis.
 ‐ Thrombotic microangiopathy.
Bleeding
 ‐ Skin and linings: ecchymoses, epistaxis, gingival bleeding, gastrointestinal bleeding, subungual hematoma, geni‐
tal bleeding, hematuria, hemoptysis, and skin hemorrhages (petechiae, purpura, and suffusions).
 ‐ Intracranial hemorrhage (epidural, subdural, subarachnoid, and intracranial).
 ‐ Vascular access bleeding.
 ‐ Parenchymal organ bleeding (including peliosis).
Table 2. Clinical presentation of coagulation abnormalities in renal diseases.
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3. Coagulation abnormalities and their clinical presentation in different 
renal diseases
3.1. Glomerulonephritis, systemic lupus, and vasculitis
Christiansen et al. [2] examined the risk of VTE in 128,096 Danish patients hospitalized for 
VTE for the period 1980–2010 (78,623 with DVT and 54,473 with PE) and compared them with 
642,426 age‐ and gender‐matched control and found that kidney disease is associated with 
higher OR for VTE (range between 1.41 for hypertensive nephropathy and 2.89 for nephritic 
syndrome), with the association being stronger during the first 3 months after the diagnosis 
of CKD but remaining elevated for the following 5 years. Therefore, the authors concluded 
that patients with chronic nephropathies are at increased risk for VTE, especially in cases of 
nephritic syndrome and glomerulonephritis.
In 182 patients with idiopathic glomerulonephritis (125 male and 57 female, mean age 
35.6 ± 13.4 years), hospitalized for the period 2000–2005, we observed thrombotic com‐
plications in 27: stroke in 6, myocardial infarction in 12, DVT in 15, PE in 7 (the sum is 
more than 27 because several patients had more than 1 thrombotic complications) [15 and 
unpublished data]. The main risk factors for the development of thrombotic incidents 
were nephrotic syndrome (OR 3.220), corticosteroid treatment (OR 2.617), and renal fail‐
ure (OR 1.51). Figure 1 shows the typical S1Q3T3 electrocardiography (ECG) changes in a 
male patient with membranous glomerulonephritis and pulmonary embolism.
Figure 1. ECG of a patient with idiopathic membranous glomerulonephritis with nephrotic syndrome and pulmonary 
embolism (PE). Typical S1Q3T3 changes.
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Marker OR (95% CI) p
Arthritis/arthralgiae 5.167 (1.433–18.627) 0.007
Serositis 2.537 (1.062–6.059) 0.034
Central nervous system involvement 9 (3.321–24.388) 0.0001
Renal involvement (LN, nephritic 
urinary sediment, proteinuria, 
nephrotic syndrome)
3.857 (1.49–9.984) 0.004
Positive IgG ACL 16.8 (6.083–46.398) 0.0001
In 106 patients with SLE (63 with biopsy‐proven lupus nephritis [LN]), 7 male and 56 female, 
mean age 37.4 ± 10.4 years; 43 without clinical/laboratory data for renal involvement, 7 male 
and 36 female, mean age 44.1 ± 17.8 years) for the period 2000–2005, we observed thrombotic 
complications in 34 patients (32.1%) (7/43 without LN and 27/63 with LN) [15]. Following 
thrombotic incidents were observed:
• Arterial thromboses: coronary incidents in 3, stroke/transient ischemic attack in 8.
• Venous thromboses: DVT in 13, PE in 6, vena axillaris/subclavia thrombosis in 1, vena cava 
inferior thrombosis in 1.
• Reproductive failure in 8.
• Disseminated intravascular coagulation in 3.
• Thrombotic microangiopathy in 1.
The sum of incidents is more than 34 because several patients had more than 1 thrombotic 
complication.
The development of thrombotic complications correlated with the presence of positive IgG 
and IgM anticardiolipin antibody (ACL) and IgG b2GPI (but not IgM b2GPI) and their lev‐
els, the presence of APS, the serum cryoglobulin levels and showed weak correlation with 
the presence of vasculitis (thrombosis+/vasculitis+ 11/106 patients vs. thrombosis−/vasculitis+ 
6/106 patients, r = 0.306, p = 0.01).
For the total population of SLE patients (with and without LN), the development of thrombotic 
complications correlated with systemic lupus erythematosus disease activity index (SLEDAI) (mean 
SLEDAI in thrombotic patients 16.2 ± 8.7 vs. 7.6 ± 3.9 for non‐thrombotic patients, r = 0.566, p = 0.0001) 
and systemic lupus collaborating clinics (SLICC) indices (mean SLICC 2.9 ± 2, vs. 0.7 ± 1.1, respec‐
tively, r = 0.593, p = 0.0001), with the presence of renal involvement (27/63 with LN vs. 7/43 without 
LN, χ2 = 8.286, r = 0.380, p = 0.004).
For the total SLE population (with and without LN), following markers for increased 
thrombotic risk were identified: arthritis/arthralgiae, serositis, central nervous system 
involvement, renal involvement, nephritic urinary sediment, nephrotic syndrome, positive 
IgG and IgM ACL and IgG (but not IgM) b2GPI antibodies, APS, corticosteroid treatment, 
and vasculitis (Table 3).
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In the investigated LN patients, the development of thrombotic complications correlated with 
the presence of vasculitis, the duration and the number of SLE criteria, the central nervous 
system involvement, oral ulcerations, arthritis/arthralgiae, LN histological activity index, the 
amount of proteinuria, serum cryoglobulin levels, the levels and positivity of IgG and IgM 
ACL, the mean IgG b2GPI levels, SLEDAI and SLICC, APS, and inversely correlated with 
serum IgG levels (lower in more severe nephrotic syndrome).
In LN patients, the following markers of increased thrombotic risk were identified: oral 
ulcerations and vasculitis, positive ANCA, central nervous system involvement, nephrotic 
syndrome, positive IgG and IgM ACL and IgG b2GPI, hypocomplementemia C3, APS, and 
corticosteroid treatment (Table 4).
The results of our studies in APS patients with and without SLE [16] showed correlation 
between CD63 expression and activated partial thromboplastin time (aPTT), CD61 expression 
and IgG and IgM ACL, and b2GPI, CD42a, and b2GPI.
Marker OR (95% CI) p
Positive IgM ACL 6.5 (2.305–18.326) 0.0001
Positive IgG b2GPI 5.672 (1.175–28.251) 0.025
APS 148.455 (18.171–1212.827) <0.0001
Corticosteroid treatment 3.220 (1.576–6.49) 0.0001
Vasculitis 5.261 (1.747–15.838) 0.001
Table 3. Markers of thrombotic risk in 106 patients with SLE [15].
Marker OR (95% CI) p
Oral ulcerations 2.0 (1.97–3.79) 0.001
Central nervous system involvement 10.54 (3.094–35.905) 0.0001
Nephrotic syndrome 2.448 (0.869–6.895) 0.05
ANCA 3.008 (1.068–8.473) 0.035
Positive IgG ACL 18.229 (5.097–65.127) <0.0001
Positive IgM ACL 7.563 (1.848–30.955) 0.002
Positive IgG b2GPI 5.238 (1.057–25.966) 0.036
Hypocomplementemia C3 2.020 (1.204–3.387) 0.015
APS 5.5 (2.939–10.294) <0.0001
Corticosteroid treatment 3.077 (1.507–6.283) 0.01
Vasculitis 17.5 (2.053–149.153) 0.001
Table 4. Markers of increased thrombotic risk in 63 LN patients [15].
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Figure 2. Biopsy specimen of retroperitoneal infiltrates in a patient with idiopathic retroperitoneal fibrosis (RPF)—
inflammatory infiltrate with abundance of lymphocytes and fibrous tissue.
The results of our investigations on the platelet activation markers in female patients with 
complicated pregnancy [18], including edema‐proteinuria‐hypertension (EPH) gestosis, 
revealed that these patients have increased anticardiolipin and beta‐2‐glycoprotein I antibod‐
ies, and the levels of ACL correlate with CD63 expression (marker of platelet degranulation). 
Some of the APL‐positive patients also had inborn coagulation defects (i.e., factor V Leiden 
20210 prothrombin gene mutation and MTHFR gene mutation).
3.2. Retroperitoneal fibrosis
Idiopathic retroperitoneal fibrosis (RPF) is a rare autoimmune fibrosing disease associated 
with the development of fibrous tissue and/or chronic inflammatory infiltrates (Figure 2) in 
the retroperitoneal space that envelops the aorta, iliac vessels, and ureters (Figure 3) [20]. 
In approximately 15% of the patients, extra‐abdominal fibrosis is observed. In some RPF 
patients with vascular involvement, thrombotic incidents have been described [20]. For the 
period 1998–2017, we followed 33 patients with idiopathic retroperitoneal fibrosis (25 male 
and 8 female). Overall 17 patients had thrombotic incidents: iliac/femoral vein thrombosis in 
8, vena cava inferior thrombosis in 4, portal vein thrombosis in 2, infiltration (with or without 
thrombosis) of the inferior mesenteric artery and its branches (Figure 4) in 3, aortic aneurism 
with thrombosis (Figure 5) in 2, DVT with or without PE in 5 (the sum of events is more 
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than 17 because several patients had more than 1 thrombotic complication). In one patient, 
the DVT episodes with varico‐ and hyrdocele (Figure 6) were the first manifestation of RPF. 
The underlying mechanism of thrombosis in RPF is associated with vascular wall changes, 
endothelial dysfunction in chronic inflammation, corticosteroid/azathioprine treatment, and 
immune phenomena (including APL).
Figure 3. CT image of a patient with idiopathic RPF. Bilateral hydronephrosis and retroperitoneal infiltrates that envelop 
the aorta, iliac vessels, and ureters.
Figure 4. Abdominal ultrasound in a patient with idiopathic RPF (arrow) with involvement of the abdominal aorta and 
inferior mesenteric artery (A and B), no Doppler data for stenosis of the inferior mesenteric artery (C). Courtesy of Dr. R. 
Krasteva‐Lolova.
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3.3. Drug abuse
The intake of illicit drugs (including heroin, cocaine, and amphetamines) has been reported to 
be associated with thrombotic incidents. The possible underlying mechanisms of thrombosis are 
overdose with rhabdomyolysis with or without acute renal failure and vascular damage; drug‐
induced endothelial cell injury with thrombotic microangiopathy; platelet and coagulation 
Figure 5. Abdominal Doppler ultrasound of a patient with idiopathic RPF with aortic aneurism.
Figure 6. Ultrasound examination of the testicles (right testicle) of a male patient with idiopathic RPF manifesting with 
femoro‐popliteal thrombosis and hydrocele.
Embolic Diseases - Unusual Therapies and Challenges76
abnormalities due to chronic inflammation, drug‐ and infection‐induced APL [11, 12, 15, 19]. 
In a group of 15 heroin abusers (12 male and 3 female, mean age 23.9 ± 4.2 years), we observed 
renal involvement in 6 [15]. One of the patients with biopsy‐proven renal involvement (chronic 
tubulo‐interstitial nephritis) and negative hepatitis B virus (HBV), hepatitis C virus (HCV), and 
human immunodeficiency virus (HIV) developed ilio‐femoral vein thrombosis and acute renal 
failure at the background of positive IgG ACL. After the cessation of heroin abuse, ACL levels 
subsided back to the normal values that suggests heroin‐induced autoantibodies. The results of 
our investigations suggest that in patients with illicit drug abuse, the clinician should be aware 
of the possible renal and thrombotic complications.
3.4. Chronic kidney disease and chronic renal failure
Chronic renal disease and chronic renal failure are associated with significantly elevated risk 
for the development of venous thromboembolism due to platelet and coagulation abnormali‐
ties, impaired fibrinolysis, and endothelial damage and dysfunction. CKD is classified in five 
stages according to the degree of glomerular filtration rate (GFR) decrease (Table 5). The preva‐
lence of CKD/CRF in adults >20 years of age in the NHANES III study [21] is approximately 
11%. This fact shows the social significance of CKD. Having in mind the increased thrombotic 
risk in mild to moderate CKD patients (1.3–2‐fold increase compared to the general population) 
and end‐stage renal disease (2.3‐fold compared to the general population), the clinician should 
be aware of VTE as a possible complication of CKD/CRF and of the need of proper anticoagula‐
tion strategy [3, 10].
3.5. Hemodialysis and peritoneal dialysis
As it was mentioned above, dialysis treatment is associated with both thrombosis and increased 
risk for bleeding episodes [1, 4–7]. The coagulation abnormalities (including the changes in the 
coagulation pathway, anticoagulation, and fibrinolysis/antifibrinolysis) in hemodialysis (HD) and 
continuous ambulatory peritoneal dialysis (CAPD) are summarized in Table 6. These changes 
are accompanied by platelet abnormalities and altered platelet‐vascular wall interactions [7]. The 
Stage GFR (ml/min/1.72 m2 body surface) Prevalence (USA, 
NHANES III, adults >20 
years of age) (%) [21]
0 >90, Normal GFR, no risk for CKD/CRF, no underlying renal disease or damage 89
1 >90, Persistent microalbuminuria and/or risk for CKD/CRF—underlying renal 
disease or damage
3.3
2 60–89 3.0
3 30–59 4.3
4 15–29 0.2
5 <15 (or dialysis treatment) 0.2
Table 5. Definition of chronic kidney disease and prevalence in the USA according to the NHANES III [21].
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in vitro and in vivo studies reveal somewhat contradictive results—patients on dialysis can 
have both increased and decreased platelet aggregation and the initiation of dialysis partially 
corrects the pre‐existing abnormalities in platelet function, characteristic for CKD/CRF [7, 9]. 
The degree of anemia and hypoalbuminemia seem to correlate with prolonged bleeding time, 
and the chronic inflammation seems to increase the thrombotic risk [7]. Heparin treatment in 
HD can induce both bleeding and thromboses (HIT II). The alterations in NO synthesis also 
lead to decreased platelet aggregation [7].
A major problem in these patients represents the vascular access thrombosis, especially in 
diabetics and in patients with systemic connective tissue disease (with or without the APS). 
Anticoagulation strategies in dialysis treatment are discussed further in the text.
3.6. Renal transplantation
VTE is a frequent complication of renal transplantation (RT). According to the literature, 6–7% 
of RT patients develop VTE [5, 22], including DVT, PE, graft thrombosis, renal vein thrombo‐
sis, and thrombotic microangiopathy [8]. The underlying mechanisms, as discussed earlier, 
include impaired platelet function and platelet‐vessel wall interactions, hypercoagulation at 
the background of chronic inflammation, corticosteroid treatment and CKD, the effect of cal‐
cineurin inhibitors and azathioprine on endothelial function, OKT3, and so on [8].
Luna et al. [5] retrospectively analyzed 577 cadaveric RTs performed for the period 1992–2009, 
excluding the cases with known hypercoagulability before RT. The incidence of VTE was 6%. 
The authors evaluated the type of thrombosis according to recipient variables, differences in 
dialysis within 24 h before transplantation (0 no dialysis, 13.8% dialysis out of hospital, and 
Marker Hemodialysis Peritoneal dialysis (CAPD)
Coagulation pathway
Fibrinogen, factor VII, vWF, tissue factor ↑ ↑
Factor II, VIII, IX, X, XII ↓ ↑
Prothrombin fragments 1 + 2 ↑ ↑
Anticoagulation
Thrombomodulin, tissue factor pathway 
inhibitor
↑ ↑
Protein S ↓ ↑
Protein C, anti‐thrombin III ↓ ‐
Fibrinolysis
Tissue plasminogen activator ↑ ↓
Plasminogen activator inhibitor 1 ↓ ↑
Thrombin activable fibrinolysis inhibitor ‐ ↑
Table 6. Coagulation abnormalities in hemodialysis and in peritoneal dialysis.
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4.2% dialysis in hospital; p = 0.029) and iliac vascular pathology (10% yes vs. 5% no; p < 0.04). 
The authors suggest that donor‐related factors are age >60 years (11% vs. 5%; p = 0.01), stroke 
versus trauma as a cause of death (9.3% vs. 4.7%; p = 0.049), and graft atheroma (16.7% yes vs. 
5.1% no; p = 0.042). The authors also investigated the treatment‐associated risk factors tacroli‐
mus versus cyclosporine (7.4% vs. 2.3%; p = 0.001) and sequential therapy (10.7% yes vs. 3.3% 
no; p = 0.001), basiliximab (adjusted for donor and recipient age, and graft atheroma). The 
multivariate analysis revealed that the predictive factors for VTE after RT (increasing the risk 
for VTE (16‐fold)) are stroke donor death (OR 3.88), recipient iliac vascular pathology (OR 
2.81), and graft atheroma (OR 3.63).
Poli et al. [22] studied 484 RT and found 7% prevalence of first episode of VTE. The 
authors investigated the importance of the cessation of oral anticoagulation and found 
that compared to VTE patients without renal disease the recurrence of VTE in RT patients 
is very high (50% or 14/28 compared to <10% or 8/84). In RT patients, the authors also find 
higher levels of homocysteine, circulating fibrinogen fragments 1 + 2 and d‐dimer that are 
characteristic for CKD/CRF patients in general. The authors recommend prolonged oral 
anticoagulation in RT patients to prevent the risk of VTE recurrence, despite the elevated 
bleeding risk.
4. Anticoagulation strategies
Due to the high risk of VTE all patients with chronic renal diseases, including glomerulone‐
phritis, systemic connective tissue diseases, and vasculitis with renal involvement, retroperi‐
toneal fibrosis, hemodialysis, should be considered possible candidates for anticoagulation, 
especially in the presence of coagulation abnormalities (anticoagulation factor deficiency, vas‐
culitis, nephrotic syndrome, and CKD/CRF) and/or predisposing factors (atrial fibrillation, 
various veins, cardiac and renal failure, etc.). Nevertheless, patients with renal diseases repre‐
sent significant therapeutic challenge if anticoagulation is needed, because they are prone to 
both thromboses and hemorrhages and because the gastrointestinal absorption and the renal 
clearance of certain anticoagulants are altered in CKD/CRF [3].
4.1. Unfractioned heparin and low‐molecular weight heparins (LMWHs)
Unfractionated heparin (UFH) is a 3–30 kDA sulphated polysaccharide that binds positively 
charged surfaces. Its anticoagulant response is mediated by binding to factor IIa and factor 
Xa. UFH anticoagulant effect is monitored using activated partial thromboplastin time (aPTT). 
UFH has reticulo‐endothelial and, to a lesser extent, renal clearance. Therefore, its clearance 
in CKD/CRF is unpredictable. UFH doses should be reduced in moderate to severe CRF (cre‐
atinine clearance below 30 ml/min) with close monitoring of aPTT (1.5–2x prolongation) in 
order to prevent over‐anticoagulation and severe bleeding episodes [6]. In VTE episodes at 
the background of CRF, Hughes et al. [3] recommend loading dose of 60 U/kg/h with main‐
tenance dose of 12 U/kg/h. Significant side effects of UFH include bleeding, heparin‐induced 
thrombocytopenia, osteopenia, and alopecia, especially in prolonged administration.
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LWMHs are synthetic UFH derivatives with shorter heparin chains and stronger affinity to 
factor Xa with lower affinity to factor IIa. Their pharmacokinetic profile is more predictable 
than that of UFH. Moreover, self‐administration of the medication is possible. LMWHs have 
lower affinity and binding to endothelial cells and platelets and no routine monitoring of 
coagulation parameters is required. The only suitable monitoring parameter is anti‐Xa levels 
that is not routinely used in clinical practice. The most frequent side effects in prolonged 
administration are HIT, osteopenia, and alopecia, and their incidence is much lower com‐
pared to that on UFH.
The LMWHs dose should also be reduced in CRF [3]:
• In glomerular filtration rate (GFR) >40 ml/min, full dose once daily.
• In GFR 30–39 ml/min, 80–90% of the recommended dose once daily.
• In GFR <30 ml/min, 60% of the recommended daily dose twice a day.
To avoid sub‐ or supradosing, monitoring of anti‐Xa levels is advisable in CRF patients with 
GFR <50 ml/min.
4.2. Warfarin and indirect anticoagulants
Indirect anticoagulants are vitamin K antagonists that inhibit the synthesis of vitamin K‐
dependent coagulation factors. The routine laboratory marker for the monitoring of their 
effect is prothrombin time (PT)/international normalized ration (INR). In CRF patients with 
GFR 30–59 ml/min, the maintenance dose required for stabile PT prolongation is 10% lower 
than that in non‐CRF population and in GFR <30 ml/min, the dose is 20% lower [3]. Moreover, 
CKD/CRF patients tend to have labile PT/INR and the anticoagulant effect is quite unpredict‐
able. In a review on mechanisms of vascular calcifications, El‐Abbadi et al. [23] emphasize 
that indirect anticoagulants can increase vascular calcifications due to vitamin K inhibi‐
tion‐dependent increase of serum phosphate levels. Another major complication is the war‐
farin‐related nephropathy—unexplained increase in serum creatinine with ≥0.3 mg% after 
the initiation of warfarin treatment probably due to intraglomerular bleeding and tubular 
obstruction by erythrocyte casts. This complication is associated with marked increase in 
mortality in CRF patients.
4.3. Newer oral anticoagulants
These medications are synthetic anti‐Xa agents (apixaban and rivaroxaban) or anti‐IIa agents 
(dabigatran and direct thrombin inhibitors). Rivaroxaban and apixaban have approximately 
30% renal clearance and their effect in CRF patients is more predictable, whereas dabiga‐
tran has mainly renal clearance (85%) and in CRF patients tends to accumulate, and its effect 
in this population is unpredictable. Therefore, rivaroxaban and apixaban are approved for 
CRF patients with CFR<30 ml/min (with dose reduction of approximately 50%, the dose of 
rivaroxaban in CFR 15–49 ml/min is 15 mg/day, and <15 ml/min is contraindicated; the dose 
of apixaban in GFR 15–29 ml/min is 2.5 mg twice a day) and dabigatran is not approved 
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in patient with GFR<30 ml/min [3]. It should be noted that both rivaroxaban and apixaban 
(anti‐Xa agents) have high protein binding and are metabolized via CYP3A4. Therefore, they 
should be used with caution in patients with nephrotic syndrome or hypoproteinemia/hypo‐
albuminemia of other origin and in combination with CYP3A4 inhibitors or inductors.
4.4. Antiaggregants
Aspirin, NSAIDs, and clopidogrel should be used with caution in patients with renal dis‐
eases because their anti‐platelet effects are unpredictable in GFR <30 ml/min, because CRF 
patients have significant platelet function abnormalities and frequently are thrombocytopenic 
and anemic and because their clearance is significantly altered in severe renal impairment. 
Moreover, NSAIDs and aspirin tend to cause severe, even life‐threatening gastrointestinal 
bleeding episodes, especially at the background of uremic gastro‐enteropathy, low platelet 
count, or corticosteroid treatment.
5. Conclusion
Patients with renal diseases are prone to both thrombosis and bleeding. The prothrombotic 
state in chronic nephropathies is associated with [6–8] vascular endothelial damage, changes 
in certain coagulation and antifibrinolytic factors, decrease in anticoagulation proteins, dyslip‐
idemia, hypoalbuminemia, changes in platelet membranes, hemo‐ and peritoneal dialysis and 
heparin treatment, increased microRNAs and circulating microparticles, antiphospholipid 
antibodies, nephrotic syndrome, anemia with high platelet count, and so on. Nevertheless, 
the same patients have substantially increased risk of bleeding due to platelet dysfunction, 
and intake of certain medications (antiaggregants, heparin and low‐molecular weight hepa‐
rins, and anemia) [6–8].
In this review, we have presented the main thrombo‐embolic risk factors in a wide variety of 
patients with renal diseases, including chronic glomerulonephritis (primary and secondary), 
CKD/CRF, idiopathic retroperitoneal fibrosis, and dialysis treatment. We have presented our 
data on thrombotic incidents in patients with glomerular and non‐glomerular diseases and 
the role of certain prothrombotic factors, such as nephrotic syndrome, inborn and acquired 
coagulation defects (i.e., factor V Leiden, MTHFR gene mutation, 20210 prothrombin gene 
mutation, and antiphospholipid antibodies), corticosteroid treatment, and so on. Therapeutic 
and prophylactic anticoagulation in these patients is influenced by many factors, including 
the underlying renal disease, renal, hepatic, and cardiac function, co‐morbidities and accom‐
panying treatment. Moreover, the doses of anticoagulant/antiaggregant and hemostatic med‐
ications should be considered carefully. The best and the safest anticoagulant medications in 
patients with chronic renal diseases (including glomerulonephritis, vasculitis, and CKD/CRF) 
at this point seem to be LMWHs followed by UFH in dose regimens in accordance with renal 
function because of their favorable safety profile, flexible dosing regimen, self‐administration, 
short and predictable action, and the possibility to correct the dose according to GFR.
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Abbreviations
ACL Anticardiolipin antibody
ADP Adenosine diphosphate
ANCA Antineutrophil cytoplasmic antibody
APL Antiphospholipid antibody
APS Antiphospholipid syndrome
aPTT Activated partial thromboplastin time
ATP Adenosine triphosphate
b2GPI Beta‐2‐glycoprotein I antibody
CAPD Continuous ambulatory peritoneal dialysis
CKD Chronic kidney disease
CRF Chronic renal failure
CRP C‐reactive protein
CT Computed tomography
DVT Deep vein thrombosis
ECG Electrocardiography
EPH Edema‐proteinuria‐hypertension
GFR Glomerular filtration rate
GIT Gastrointestinal tract
GP Glycoprotein
HBV Hepatitis B virus
HCV Hepatitis C virus
HD Hemodialysis
HIT II Heparin‐induced thrombocytopenia type II
HIV Human immunodeficiency virus
IL‐6 Interleukin 6
INR International normalized ration
LMWH Low‐molecular weight heparin
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LN Lupus nephritis
MPs Microparticles
MTHFR Methylene tetrahydrofolate reductase
NF‐kB Nuclear factor kappa‐B
NO Nitric oxide
NSAIDs Non‐steroid anti‐inflammatory drugs
PAI‐1 Plasminogen activator inhibitor 1
PD Peritoneal dialysis
PE Pulmonary embolism
PGI2 Prostaglandin I2
PT Prothrombin time
PTH Parathyroid hormone
RAAS Rennin‐angiotensin‐aldosterone system
RPF Retroperitoneal fibrosis
RT Renal transplantation
SLE Systemic lupus erythematosus
SLEDAI Systemic lupus erythematosus disease activity index
SLICC systemic lupus collaborating clinics
TF Tissue factor
tPA Tissue plasminogen activator
UFH Unfractionated heparin
VTE Venous thromboembolism
vWF Von Willebrand factor
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